DNA Script Raises $38.5 Million in Series B Financing

Oversubscribed round led by LSP will fund accelerated product
development and commercial operations in the U.S.

PARIS–(BUSINESS WIRE)–DNA Script today announced an oversubscribed Series B fundraising of
$38.5M led by LSP, one of Europe’s largest and most experienced
healthcare investment firms. Bpifrance, through its Large Venture fund,
joined the round, alongside existing investors Illumina Ventures, M.
Ventures, Sofinnova Partners, Kurma Partners and Idinvest Partners. The
proceeds will enable DNA Script to accelerate the development of the
company’s first products based on its industry-leading enzymatic
technology for de novo synthesis of nucleic acids. The company is
prioritizing the recruitment of top talent in the U.S. for its product
development and commercialization teams in preparation for product
launch, as well as on expanding its Paris-based research team.

DNA Script’s innovative technology provides affordable, rapid,
high-quality production of important genomic experimental precursors,
such as oligonucleotides. The technology overcomes many of the
inefficiencies of today’s synthetic DNA production. It features a novel
biochemical process for nucleic acids synthesis based on the use of
highly efficient enzymes, thus enabling enhanced performance while
minimizing the use of harsh chemicals. The product portfolio based on
DNA Script’s proprietary enzymatic synthesis platform will enable
molecular biology researchers to accelerate their experiments — with the
goal of moving from design to results within a day for a broad range of
applications.

“In less than two years since our last financing round, the DNA
Script team has developed enzymatic synthesis technology at an
incredibly fast pace and extended the company’s lead in this exciting
and quickly expanding sector. As we announced earlier this year at the
AGBT General Meeting, DNA Script was the first company to enzymatically
synthesize a 200mer oligo de novo with an average coupling efficiency
that rivals the best organic chemical processes in use today. Our
technology is now reliable enough for its first commercial applications,
which we believe will deliver the promise of same-day results to
researchers everywhere, with DNA synthesis that can be completed in just
a few hours,”
said Thomas Ybert, CEO and cofounder of DNA Script.

“We are thrilled to lead this round with participation of such a
respected group of founders and investors. We see DNA Script as the
clear leader in this nascent field,”
said Joachim (JR) Rothe,
Managing Partner at LSP and new member of DNA Script’s board. “The
progress made by DNA Script in only two years is amazing, and we believe
the company will shift the current DNA synthesis paradigm, not only in
the research market but also in the broader pharma business — for
personalized therapies and diagnostics in particular.”

About DNA Script
Founded in 2014 in Paris, DNA Script is the
world’s leading company in manufacturing de novo synthetic nucleic acids
using an enzymatic technology. The company aims at accelerating
innovation in life sciences and technology through rapid, affordable,
and high-quality DNA synthesis. DNA Script’s approach leverages nature’s
billions of years of evolution in synthesizing DNA to enable genome
scale synthesis. The Company’s technology has the potential to greatly
accelerate the development of new therapeutics, sustainable chemicals
production, improved crops as well as data storage.
www.dnascript.co

Contacts

Press contacts in Europe
ALIZE RP
Caroline
Carmagnol and Tatiana Vieira
DNASCRIPT@alizerp.com
06
64 18 99 59 / 01 44 54 36 65

Press contact in the US
SEISMIC
Eric Schubert
eric@teamseismic.com
+415-9394366

DNA Script Contact
Sylvain Gariel, COO
sg@dnascript.co